Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

Autor: Barry, H, Mutua, G, Kibuuka, H, Anywaine, Z, Sirima, SB, Meda, N, Anzala, O, Eholie, S, Bétard, C, Richert, L, Lacabaratz, C, McElrath, MJ, de Rosa, S, Cohen, KW, Shukarev, G, Robinson, C, Gaddah, A, Heerwegh, D, Bockstal, V, Luhn, K, Leyssen, M, Douoguih, M, Thiébaut, R, Thiebaut, R

Publikováno v: PLoS Medicine, Vol 18, Iss 10 (2021)
PLoS Medicine, Vol 18, Iss 10, p e1003813 (2021)

Background We investigated safety, tolerability, and immunogenicity of the heterologous 2-dose Ebola vaccination regimen in healthy and HIV-infected adults with different intervals between Ebola vaccinations. Methods and findings In this randomised,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::6f3976241827ac97474f5ced9d54f966
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555783/?tool=EBI

Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells.

Autor: Streeck H, Brumme ZL, Anastario M, Cohen KW, Jolin JS, Meier A, Brumme CJ, Rosenberg ES, Alter G, Allen TM, Walker BD, Altfeld M, Streeck, Hendrik, Brumme, Zabrina L, Anastario, Michael, Cohen, Kristin W, Jolin, Jonathan S, Meier, Angela, Brumme, Chanson J, Rosenberg, Eric S

Publikováno v: PLoS Medicine; May2008, Vol. 5 Issue 5, pe100-e100, 1p

Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans.

Autor: Williams WB; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA; Department of Integrative Immunobiology, Duke School of Medicine, Durham, NC 27710, USA. Electronic address: wilton.williams@duke.edu., Alam SM; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA. Electronic address: munir.alam@duke.edu., Ofek G; Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA; Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA., Erdmann N; University of Alabama Medical Center, Birmingham, AL 35223, USA., Montefiori DC; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA., Seaman MS; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA., Wagh K; Los Alamos National Laboratory, Los Alamos, NM 87545, USA; New Mexico Consortium, Los Alamos, NM 87544, USA., Korber B; Los Alamos National Laboratory, Los Alamos, NM 87545, USA; New Mexico Consortium, Los Alamos, NM 87544, USA., Edwards RJ; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA., Mansouri K; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Eaton A; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA., Cain DW; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA., Martin M; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Hwang J; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Arus-Altuz A; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Lu X; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Cai F; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA., Jamieson N; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA., Parks R; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Barr M; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Foulger A; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Anasti K; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Patel P; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Sammour S; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Parsons RJ; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Huang X; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Lindenberger J; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Fetics S; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Janowska K; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Niyongabo A; Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA., Janus BM; Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA; Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA., Astavans A; Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA., Fox CB; Access to Advanced Health Institute, Seattle, WA 98102, USA., Mohanty I; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Evangelous T; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Chen Y; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Berry M; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Kirshner H; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Van Itallie E; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA., Saunders KO; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA; Department of Integrative Immunobiology, Duke School of Medicine, Durham, NC 27710, USA; Department of Molecular Genetics and Microbiology, Duke School of Medicine, Durham, NC 27710, USA., Wiehe K; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA., Cohen KW; Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., McElrath MJ; Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Corey L; Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Acharya P; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA; Department of Biochemistry, Duke School of Medicine, Durham, NC 27710, USA., Walsh SR; Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: swalsh@bwh.harvard.edu., Baden LR; Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: lbaden@bwh.harvard.edu., Haynes BF; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA; Department of Integrative Immunobiology, Duke School of Medicine, Durham, NC 27710, USA; Duke Global Health Institute, Duke School of Medicine, Durham, NC 27710, USA. Electronic address: barton.haynes@duke.edu.

Publikováno v: Cell [Cell] 2024 Jun 06; Vol. 187 (12), pp. 2919-2934.e20. Date of Electronic Publication: 2024 May 17.

Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming.

Autor: deCamp AC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA. adecamp@scharp.org., Corcoran MM; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, SE-171 77, Stockholm, Sweden., Fulp WJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA., Willis JR; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.; Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, 92037, USA.; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, 92037, USA., Cottrell CA; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.; Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, 92037, USA.; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, 92037, USA., Bader DLV; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.; Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, 92037, USA.; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, 92037, USA., Kalyuzhniy O; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.; Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, 92037, USA.; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, 92037, USA., Leggat DJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Cohen KW; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA., Hyrien O; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA., Menis S; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.; Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, 92037, USA.; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, 92037, USA., Finak G; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA., Ballweber-Fleming L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA., Srikanth A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Plyler JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Rahaman F; IAVI, 125 Broad Street, 9th floor, New York, NY, 10004, USA., Lombardo A; IAVI, 125 Broad Street, 9th floor, New York, NY, 10004, USA., Philiponis V; IAVI, 125 Broad Street, 9th floor, New York, NY, 10004, USA., Whaley RE; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA., Seese A; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA., Brand J; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Ruppel AM; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Hoyland W; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Mahoney CR; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA., Cagigi A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Taylor A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Brown DM; The Foundation for the National Institutes of Health, North Bethesda, MD, USA., Ambrozak DR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Sincomb T; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.; Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, 92037, USA.; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, 92037, USA., Mullen TM; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.; Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, 92037, USA.; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, 92037, USA., Maenza J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA.; Department of Medicine, University of Washington, Seattle, WA, 98195, USA., Kolokythas O; Department of Radiology, University of Washington, Seattle, WA, 98195, USA., Khati N; Department of Radiology, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA., Bethony J; Department of Microbiology, Immunology and Tropical Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA., Roederer M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Diemert D; Department of Microbiology, Immunology and Tropical Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.; Department of Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA., Koup RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Laufer DS; IAVI, 125 Broad Street, 9th floor, New York, NY, 10004, USA., McElrath JM; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA., McDermott AB; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Karlsson Hedestam GB; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, SE-171 77, Stockholm, Sweden. gunilla.karlsson.hedestam@ki.se., Schief WR; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, 92037, USA. schief@scripps.edu.; Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, 92037, USA. schief@scripps.edu.; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, 92037, USA. schief@scripps.edu.; The Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, 02139, USA. schief@scripps.edu.; Moderna Inc., Cambridge, MA, 02139, USA. schief@scripps.edu.

Publikováno v: NPJ vaccines [NPJ Vaccines] 2024 Mar 11; Vol. 9 (1), pp. 58. Date of Electronic Publication: 2024 Mar 11.

mRNA vaccination boosts S-specific T cell memory and promotes expansion of CD45RA int T EMRA -like CD8 ⁺ T cells in COVID-19 recovered individuals.

Autor: Mayer-Blackwell K; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Ryu H; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Codd AS; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Parks KR; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., MacMillan HR; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Cohen KW; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Stewart TL; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Seese A; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Lemos MP; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., De Rosa SC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Czartoski JL; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Moodie Z; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Nguyen LT; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., McGuire DJ; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA., Ahmed R; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA., Fiore-Gartland A; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Electronic address: jmcelrat@fredhutch.org., Newell EW; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Electronic address: enewell@fredhutch.org.

Publikováno v: Cell reports. Medicine [Cell Rep Med] 2023 Aug 15; Vol. 4 (8), pp. 101149. Date of Electronic Publication: 2023 Aug 07.